WaveMan
WaveMan · Company
MEDS · Datameds Ai, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

MEDS DataMeds AI (MEDS) Insider Trading, Ownership & Congress Trades

Wholesale & Retail · Wholesale-drugs, proprietaries & druggists' sundries · CIK 0002030763
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

DataMeds AI insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for DataMeds AI, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Fell Donald G.
Director
BUY
2022-08-29 SECtraded 2022-08-25
1,500
$1.6K
-98.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 12, 2022.
  • The trade is 7.1% of the 21,139 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Director Fell Donald G. bought about $1.6K of MEDS on Aug 25, 2022.
AJJARAPU SURENDRA K
CEO
BUY
2022-05-23 SECtraded 2022-05-20
10,000
$13.0K
-98.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 4.5% of the 222,500 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: CEO AJJARAPU SURENDRA K bought about $13.0K of MEDS on May 20, 2022, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
Fell Donald G.
Director
BUY
2022-05-18 SECtraded 2022-05-12
2,000
$2.5K
-98.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 10.2% of the 19,639 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: Director Fell Donald G. bought about $2.5K of MEDS on May 12, 2022, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
3 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+28.7% year over year
more than 89% of Wholesale & Retail
Margin
-433.9% net margin
below 99% of Wholesale & Retail
Buybacks
no share repurchases reported
Short interest
36.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
more than 96% of Wholesale & Retail
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch MEDS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-89.1%12M
-96%-2%+92%+185%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MEDS: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in MEDS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MEDS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
CVNAWMTAMZNSNXWRVLVAZOPSMTWLFCTDUPURBNTTSH

MEDS financials

Revenue growth
+28.7%
XBRL, annual
Net margin
-433.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$8.0M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-1,100%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.43x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
n/a
average equity is zero or negative
Return on assets
-203.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-2,720%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$36.1M
market value at close 2026-10-26 on 2026-08-17 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenue$23.3M$18.1Mn/a
Gross profit-$6.4M$1.8Mn/a
Operating income-$93.7M-$6.1M-$2.9M
Net income-$101.3M-$6.9M-$2.9M
EPS (diluted)-1.43-0.15-0.06
Operating cash flow-$10.9M-$1.2M-$349.1K
Cash$42.6K$1.0M$1.4K
Long-term debt$12.6M$11.5Mn/a
SEC XBRL, fiscal years, as known on 2026-10-28

MEDS Stock Sonar score 4/7 axes

Find similar shapesCompare

MEDS ranks highest on growth (89th percentile) and risk and compliance (49th), and lowest on profitability (3rd), among Wholesale & Retail peers.

Profitability
3
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-203.0% · 5 pct, sector of 257
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-2720% · 0 pct, sector of 220
Financial health
11
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.43x · 11 pct, sector of 210
Growth
89
Inputs
  • Revenue growth, YoY+28.7% · 89 pct, sector of 311
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
49
Inputs
  • Short interest, % of float+36.1% · 2 pct, sector of 320
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+2.6% · 96 pct, sector of 226
3 not measured: Insider conviction, Institutional and government, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies